Drug intelligence / Profile preview

diflucortolone valerate + isoconazole nitrate

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Topical

Overview

A topical medication combining diflucortolone valerate (0.1%), a potent fluorinated corticosteroid, with isoconazole nitrate (1%), a broad-spectrum antimycotic azole. This combination is used for treating superficial fungal infections of the skin accompanied by inflammatory or eczematous conditions. Diflucortolone valerate provides anti-inflammatory, antipruritic, and vasoconstrictive effects, while isoconazole nitrate offers antimycotic activity against dermatophytes, yeasts, yeast-like fungi, molds, and gram-positive bacteria.

Brand names: Travocort
Other names: isoconazole nitrate + diflucortolone valerate

Targets

GR (Glucocorticoid receptor)PLA2 (Phospholipase A2 group IID)CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on diflucortolone valerate + isoconazole nitrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diflucortolone valerate + isoconazole nitrate.

Explore the full profile